Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

MB-CART19.1 Cellular Therapy for the Treatment of Relapsed or Refractory Central Nervous System Lymphoma

Trial Status: active

This phase I trial studies the side effects and best dose of MB-CART19.1 cellular therapy in treating patients with central nervous system (CNS) lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). MB-CART19.1 is a cellular therapy that is made from a patient's own white blood cells (called T cells). T cells are immune system cells that protect the body from infections, cancer, and other possible harms. Some types of cancer can block T cells from attacking the cancer cells. MB-CART19.1 is made by collecting patient T cells and adding a gene (a small piece of deoxyribonucleic acid [DNA]) from a virus, which helps the T cells recognize and destroy the cancer cells. These genetically changed (modified) T cells are called chimeric antigen receptor (CAR) T cells, and treatments made from them are called CAR T-cell therapies. MB-CART19.1 may be safe in treating patients with relapsed or refractory CNS lymphoma.